<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02481141</url>
  </required_header>
  <id_info>
    <org_study_id>SBIP12-002F</org_study_id>
    <nct_id>NCT02481141</nct_id>
  </id_info>
  <brief_title>Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes</brief_title>
  <official_title>Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SBI Pharmaceuticals Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SBI Pharmaceuticals Co, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to assess the safety and preliminary efficacy of 5-ALA - SFC
      at doses up to 200 mg per day in subjects with type II diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to assess the safety of 5-ALA - SFC at doses up to 200 mg per day in
      subjects with type II diabetes mellitus. Safety will be assessed by the incidence of adverse
      events and clinically significant laboratory results.

      The secondary objective is to assess the efficacy of 5-ALA-SFC at doses up to 200 mg per day
      on glycemic control in subjects with type II diabetes mellitus. Efficacy measures will
      include fasting plasma glucose level, HbA1c level, lipid profile, and body weight.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Week 2, Week 4, Week 12</time_frame>
    <description>The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 12</time_frame>
    <description>The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2 Hour Post Meal Glucose Level</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 12</time_frame>
    <description>Change from baseline in blood glucose levels 2 hours after breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline, Week 6, Week 12</time_frame>
    <description>Change from baseline measured at week 6 and week 12 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 12</time_frame>
    <description>Change from baseline in HbA1c %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol (Component of Lipid Profile)</measure>
    <time_frame>Baseline, Week 6, Week 12</time_frame>
    <description>Change from baseline measured at week 6 and week 12 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline LDL (Component of Lipid Profile)</measure>
    <time_frame>Baseline, Week 6, Week 12</time_frame>
    <description>Change from baseline measured at week 6 and week 12 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HDL (Component of Lipid Profile)</measure>
    <time_frame>Baseline, Week 6, Week 12</time_frame>
    <description>Change from baseline measured at week 6 and week 12 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides (Component of Lipid Profile)</measure>
    <time_frame>Baseline, Week 6, Week 12</time_frame>
    <description>Change from baseline measured at week 6 and week 12 only</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>5-ALA-SFC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study product administration will be as follows:
Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study matching placebo administration will be as follows:
Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-ALA-SFC</intervention_name>
    <description>Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC</description>
    <arm_group_label>5-ALA-SFC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females residing in Bahrain aged 20 to 75 years old

          2. Otherwise in good health in the opinion of the investigator based on results of
             medical history, physical exam and laboratory assessments

          3. Diagnosed with type II diabetes mellitus with HbA1c &gt;6.5 and &lt;10% which is
             uncontrolled despite the use of one or more glycemia-lowering drugs

          4. BMI ≤44 kg/m2

          5. Sitting BP ≤ 160/100mm Hg

          6. Sleep apnea screening is negative

          7. Ophthalmological exam is within normal limits as judged by the investigator. If
             findings are observed, they must be judged as not clinically significant.

          8. Female subjects are not pregnant, not breast-feeding, and if of childbearing
             potential, have agreed to use an acceptable method of birth control

        Exclusion Criteria:

          1. Liver dysfunction defined as liver function tests &gt;1.5 times upper limit of normal

          2. Renal dysfunction defined as BUN and/or serum creatinine &gt;1.5 times upper limit of
             normal and/or eGFR &lt;30 ml/min/1.73 m2

          3. History of any life-threatening disease, cardiovascular disease, viral hepatitis,
             porphyria or hemochromatosis

          4. Allergy to ALA, SFC, or any other component of study product

          5. Use of insulin for management of serum glucose

          6. Hypoglycemic event within the previous 3 months, defined as serum glucose levels less
             than 70 mg/dL

          7. History of sickle cell anemia disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riyadh Rehani, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>SBI Pharmaceuticals Co, Ltd.</affiliation>
  </overall_official>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <results_first_submitted>November 3, 2016</results_first_submitted>
  <results_first_submitted_qc>November 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2017</results_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>5-ALA-SFC</title>
          <description>Study product administration will be as follows:
Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks
5-ALA-SFC: Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA – SFC</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Study matching placebo administration will be as follows:
Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat Population (ITT) included all patients who took at least one dose of study product and had at least one post-baseline efficacy evaluation</population>
      <group_list>
        <group group_id="B1">
          <title>5-ALA-SFC</title>
          <description>Study product administration will be as follows:
Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks
5-ALA-SFC: Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA – SFC</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Study matching placebo administration will be as follows:
Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="6.51"/>
                    <measurement group_id="B2" value="51.9" spread="5.07"/>
                    <measurement group_id="B3" value="52.2" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bahrain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA – SFC in a population of patients with type 2 diabetes mellitus living in Bahrain.</description>
        <time_frame>Week 2, Week 4, Week 12</time_frame>
        <population>Safety population included all subjects who took at least one dose of study product.</population>
        <group_list>
          <group group_id="O1">
            <title>5-ALA-SFC Through Week 2 (50 mg 2x/Day)</title>
            <description>Study product administration will be as follows:
Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>5-ALA-SFC Through Week 4 (75 mg 2x/Day)</title>
            <description>Study product administration will be as follows:
Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>5-ALA-SFC Through Week 12 (100 mg 2x/Day)</title>
            <description>Study product administration will be as follows:
Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo Through Week 2</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 0: 1 capsule twice per day for 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo Through Week 4</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 2: 1 capsule twice per day for 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo Through Week 12</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 4: 1 capsule twice per day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA – SFC in a population of patients with type 2 diabetes mellitus living in Bahrain.</description>
          <population>Safety population included all subjects who took at least one dose of study product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fasting Blood Glucose</title>
        <description>The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA – SFC in a population of patients with type 2 diabetes mellitus living in Bahrain.</description>
        <time_frame>Baseline, Week 2, Week 4, Week 12</time_frame>
        <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline</title>
            <description>Study product administration will be as follows:
Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline</title>
            <description>Study product administration will be as follows:
Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>5-ALA-SFC Through Wk 12 (100 mg 2x/Day) Change From Baseline</title>
            <description>Study product administration will be as follows:
Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo Through Week 2 Change From Baseline</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 0: 1 capsule twice per day for 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo Through Week 4 Change From Baseline</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 2: 1 capsule twice per day for 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo Through Week 12 Change From Baseline</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 4: 1 capsule twice per day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose</title>
          <description>The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA – SFC in a population of patients with type 2 diabetes mellitus living in Bahrain.</description>
          <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.4"/>
                    <measurement group_id="O2" value="-0.2" spread="4.9"/>
                    <measurement group_id="O3" value="-3.0" spread="4.4"/>
                    <measurement group_id="O4" value="-7.3" spread="5.2"/>
                    <measurement group_id="O5" value="-0.8" spread="7.2"/>
                    <measurement group_id="O6" value="-4.2" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2 Hour Post Meal Glucose Level</title>
        <description>Change from baseline in blood glucose levels 2 hours after breakfast</description>
        <time_frame>Baseline, Week 2, Week 4, Week 12</time_frame>
        <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline</title>
            <description>Study product administration will be as follows:
Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline</title>
            <description>Study product administration will be as follows:
Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>5-ALA-SFC Through Week 12 (100 mg 2x/Day) Change From Baseline</title>
            <description>Study product administration will be as follows:
Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo Through Week 2 Change From Baseline</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 0: 1 capsule twice per day for 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo Through Week 4 Change From Baseline</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 2: 1 capsule twice per day for 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo Through Week 12 Change From Baseline</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 4: 1 capsule twice per day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2 Hour Post Meal Glucose Level</title>
          <description>Change from baseline in blood glucose levels 2 hours after breakfast</description>
          <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.1"/>
                    <measurement group_id="O2" value="-12.9" spread="6.1"/>
                    <measurement group_id="O3" value="-8.5" spread="9.8"/>
                    <measurement group_id="O4" value="-26.5" spread="7.8"/>
                    <measurement group_id="O5" value="-18.8" spread="9.9"/>
                    <measurement group_id="O6" value="-33.0" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight</title>
        <description>Change from baseline measured at week 6 and week 12 only</description>
        <time_frame>Baseline, Week 6, Week 12</time_frame>
        <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>5-ALA-SFC Through Week 6 Change From Baseline</title>
            <description>Week 6: 1 capsule of 100mg 5-ALA-SFC twice per day</description>
          </group>
          <group group_id="O2">
            <title>5-ALA-SFC Through Week 12 Change From Baseline</title>
            <description>Week 12: 1 capsule of 100mg 5-ALA-SFC twice per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo Through Week 6 Change From Baseline</title>
            <description>Week 6: 1 placebo capsule twice per day</description>
          </group>
          <group group_id="O4">
            <title>Placebo Through Week 12 Change From Baseline</title>
            <description>Week 12: 1 placebo capsule twice per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight</title>
          <description>Change from baseline measured at week 6 and week 12 only</description>
          <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.5"/>
                    <measurement group_id="O2" value="-0.2" spread="0.3"/>
                    <measurement group_id="O3" value="-0.3" spread="0.7"/>
                    <measurement group_id="O4" value="-0.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c</title>
        <description>Change from baseline in HbA1c %</description>
        <time_frame>Baseline, Week 2, Week 4, Week 12</time_frame>
        <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline</title>
            <description>Study product administration will be as follows:
Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>5-ALA-SFC Through 4 (75 mg 2x/Day) Change From Baseline</title>
            <description>Study product administration will be as follows:
Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>5-ALA-SFC Through 12 (100 mg 2x/Day) Change From Baseline</title>
            <description>Study product administration will be as follows:
Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo Through Week 2 Change From Baseline</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 0: 1 capsule twice per day for 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo Through Week 4 Change From Baseline</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 2: 1 capsule twice per day for 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo Through Week 12 Change From Baseline</title>
            <description>Study matching placebo administration will be as follows:
Beginning Week 4: 1 capsule twice per day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c</title>
          <description>Change from baseline in HbA1c %</description>
          <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.1"/>
                    <measurement group_id="O2" value="-0.3" spread="0.1"/>
                    <measurement group_id="O3" value="-0.7" spread="0.2"/>
                    <measurement group_id="O4" value="-0.5" spread="0.2"/>
                    <measurement group_id="O5" value="-0.5" spread="0.2"/>
                    <measurement group_id="O6" value="-0.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol (Component of Lipid Profile)</title>
        <description>Change from baseline measured at week 6 and week 12 only</description>
        <time_frame>Baseline, Week 6, Week 12</time_frame>
        <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>5-ALA-SFC Through Week 6 Change From Baseline</title>
            <description>Week 6: 1 capsule of 100mg 5-ALA-SFC twice per day</description>
          </group>
          <group group_id="O2">
            <title>5-ALA-SFC Through Week 12 Change From Baseline</title>
            <description>Week 12: 1 capsule of 100mg 5-ALA-SFC twice per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo Through Week 6 Change From Baseline</title>
            <description>Week 6: 1 placebo capsule twice per day</description>
          </group>
          <group group_id="O4">
            <title>Placebo Through Week 12 Change From Baseline</title>
            <description>Week 12: 1 placebo capsule twice per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol (Component of Lipid Profile)</title>
          <description>Change from baseline measured at week 6 and week 12 only</description>
          <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="3.7"/>
                    <measurement group_id="O2" value="6.8" spread="3.5"/>
                    <measurement group_id="O3" value="-7.6" spread="5.5"/>
                    <measurement group_id="O4" value="-0.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline LDL (Component of Lipid Profile)</title>
        <description>Change from baseline measured at week 6 and week 12 only</description>
        <time_frame>Baseline, Week 6, Week 12</time_frame>
        <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>5-ALA-SFC Through Week 6 Change From Baseline</title>
            <description>Week 6: 1 capsule of 100mg 5-ALA-SFC twice per day</description>
          </group>
          <group group_id="O2">
            <title>5-ALA-SFC Through Week 12 Change From Baseline</title>
            <description>Week 12: 1 capsule of 100mg 5-ALA-SFC twice per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo Through Week 6 Change From Baseline</title>
            <description>Week 6: 1 placebo capsule twice per day</description>
          </group>
          <group group_id="O4">
            <title>Placebo Through Week 12 Change From Baseline</title>
            <description>Week 12: 1 placebo capsule twice per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline LDL (Component of Lipid Profile)</title>
          <description>Change from baseline measured at week 6 and week 12 only</description>
          <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.2"/>
                    <measurement group_id="O2" value="7.6" spread="3.3"/>
                    <measurement group_id="O3" value="-11.8" spread="4.7"/>
                    <measurement group_id="O4" value="-4.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HDL (Component of Lipid Profile)</title>
        <description>Change from baseline measured at week 6 and week 12 only</description>
        <time_frame>Baseline, Week 6, Week 12</time_frame>
        <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>5-ALA-SFC Through Week 6 Change From Baseline</title>
            <description>Week 6: 1 capsule of 100mg 5-ALA-SFC twice per day</description>
          </group>
          <group group_id="O2">
            <title>5-ALA-SFC Through Week 12 Change From Baseline</title>
            <description>Week 12: 1 capsule of 100mg 5-ALA-SFC twice per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo Through Week 6 Change From Baseline</title>
            <description>Week 6: 1 placebo capsule twice per day</description>
          </group>
          <group group_id="O4">
            <title>Placebo Through Week 12 Change From Baseline</title>
            <description>Week 12: 1 placebo capsule twice per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HDL (Component of Lipid Profile)</title>
          <description>Change from baseline measured at week 6 and week 12 only</description>
          <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.0"/>
                    <measurement group_id="O2" value="0.5" spread="1.0"/>
                    <measurement group_id="O3" value="-1.6" spread="1.4"/>
                    <measurement group_id="O4" value="-1.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides (Component of Lipid Profile)</title>
        <description>Change from baseline measured at week 6 and week 12 only</description>
        <time_frame>Baseline, Week 6, Week 12</time_frame>
        <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>5-ALA-SFC Through Week 6 Change From Baseline</title>
            <description>Week 6: 1 capsule of 100mg 5-ALA-SFC twice per day</description>
          </group>
          <group group_id="O2">
            <title>5-ALA-SFC Through Week 12 Change From Baseline</title>
            <description>Week 12: 1 capsule of 100mg 5-ALA-SFC twice per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo Through Week 6 Change From Baseline</title>
            <description>Week 6: 1 placebo capsule twice per day</description>
          </group>
          <group group_id="O4">
            <title>Placebo Through Week 12 Change From Baseline</title>
            <description>Week 12: 1 placebo capsule twice per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides (Component of Lipid Profile)</title>
          <description>Change from baseline measured at week 6 and week 12 only</description>
          <population>Intent‐to‐Treat Population (ITT) included all subjects who took at least one dose of study product and had at least one post‐baseline efficacy evaluation. Change from Baseline was calculated as the mean for the visit compared to baseline mean for only the subjects with a result for that visit.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="14.6"/>
                    <measurement group_id="O2" value="3.2" spread="11.1"/>
                    <measurement group_id="O3" value="4.5" spread="21.1"/>
                    <measurement group_id="O4" value="11.9" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events were collected during the 12 week period subjects were in the study and taking either 5-ALA-SFC or Placebo.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>5-ALA-SFC Through Week 2</title>
          <description>Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>5-ALA-SFC Through Week 4</title>
          <description>Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>5-ALA-SFC Through Week 12</title>
          <description>Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo Through Week 2</title>
          <description>Beginning Week 0: 1 placebo capsule twice per day for 2 weeks</description>
        </group>
        <group group_id="E5">
          <title>Placebo Through Week 4</title>
          <description>Beginning Week 2: 1 placebo capsule twice per day for 2 weeks</description>
        </group>
        <group group_id="E6">
          <title>Placebo Through Week 12</title>
          <description>Beginning Week 4: 1 placebo capsule twice per day for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess in the nose</sub_title>
                <description>One serious adverse event of a nasal abscess requiring hospitalization was reported by a subject receiving 5-ALA-SFC, which was not related to study product.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Riyadh Rehani, President of MENA Region</name_or_title>
      <organization>SBI Pharmaceuticals Co, Ltd.</organization>
      <phone>+973 66394100</phone>
      <email>rrehani@sbigroup.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

